Is ticagrelor worth its high cost and side-effects?
Acta Cardiol
; 74(2): 93-98, 2019 Apr.
Article
em En
| MEDLINE
| ID: mdl-29730968
ABSTRACT
Ticagrelor is a reversible P2Y12 receptor antagonist that is more potent than clopidogrel. When used in combination with aspirin, it reduces cardiovascular events in patients with acute coronary syndrome. However, unbiased review of 5 randomised controlled trials indicates that although statistically significant, the clinical superiority of ticagrelor over clopidogrel is modest. Thus, identification of patients who benefit the most from ticagrelor is a priority. Besides bleeding issues, ticagrelor can frequently cause bouts of dyspnoea, which requires ticagrelor replacement by another P2Y12 receptor antagonist, with a loading dose.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Custos de Medicamentos
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
Síndrome Coronariana Aguda
/
Ticagrelor
Tipo de estudo:
Clinical_trials
/
Health_economic_evaluation
/
Incidence_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article